What SciGen Korea Ltd. does

SciGen Korea Ltd. is a South Korea-based biopharmaceutical subsidiary of Singapore-incorporated SciGen Pte. Ltd., employing approximately 12 people. The company markets and commercializes an integrated portfolio of healthcare products organized across three segments: Brand Drugs, Generics/Biosimilars, and Medical Devices. Its proprietary assets include Lorelin (the first GnRHa developed in Korea with an international patent), SciXeg (a pegfilgrastim biosimilar approved by both the FDA and EMA), SciLocyte (the first Filgrastim in pre-filled syringe format), SciTropin A (a European-quality recombinant human growth hormone in ready-to-use format), and the LTU-904 low-level laser treatment device for post-mastectomy lymphoedema. The portfolio also extends to in-licensed or distributed products such as Zometa, Diphereline, Gensulin/SciLin, ISCADOR, HERI, Zinc-S, and NeoTrace 4, spanning oncology, endocrinology, hematology, and supportive care.

SciGen operates a sales-led go-to-market built on out-licensing, partner due diligence, market analysis, and distribution agreements with manufacturers and channel partners. Products are commercialized across 12+ Asia-Pacific and emerging markets including South Korea, Philippines, Australia, Singapore, Malaysia, Vietnam, Hong Kong, Thailand, Taiwan, Indonesia, Brunei, and New Zealand. Revenue is generated through pharmaceutical product sales and licensing/distribution arrangements, with quote-based pricing through healthcare providers and distributors rather than disclosed list pricing. The customer base is described as healthcare providers and patients globally, with no named anchor customers or segment-level revenue disclosure.

The company is privately held with no disclosed funding rounds, institutional investors, or public listing. Its operating structure is lean relative to its geographic footprint, with a small team executing commercialization rather than in-house drug discovery. Strategic emphasis is on continuous portfolio fill and improvement across the three product categories, leveraging international regulatory approvals as a primary differentiation lever.

Name

SciGen Korea Ltd.

Legal name

SciGen Pte. Ltd.

Website

https://scigen.co.kr

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

SciGen Korea Ltd. is a Seoul-based biopharmaceutical subsidiary of Singapore's SciGen Pte. Ltd. that markets and commercializes brand drugs, generics/biosimilars, and medical devices across 12+ Asia-Pacific and emerging markets, serving healthcare providers and patients in oncology, endocrinology, and supportive care.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Commercialization

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Surgical and Medical Instrument Manufacturing (339112), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD), Women’s Health & Reproductive Specialty Pharmaceuticals (HLAIACAN), Specialty Pharmacy & Biologics Distribution (CRAOAHAD)

Keywords

• Biopharmaceutical products
• Generic pharmaceuticals
• Biosimilars distribution
• Medical devices marketing
• Oncology supportive care

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Marketing or Sales, Operations, Personnel, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: SciGen generates revenue through the marketing and commercialization of innovative healthcare products including brand drugs, generics, biosimilars, and medical devices. The company markets products worldwide across multiple countries including South Korea, Philippines, Australia, Singapore, Malaysia, Vietnam, Hong Kong, Thailand, Taiwan, Indonesia, Brunei, and New Zealand.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

SciGen Korea markets and commercializes an integrated biopharmaceutical portfolio across Brand Drugs, Generics/Biosimilars, and Medical Devices for oncology supportive care, endocrinology, hematology, and immunology. The company distributes proprietary products such as Lorelin (GnRHa) and SciXeg (pegfilgrastim biosimilar), along with partnered brands like Zometa, Diphereline, Gensulin, and the LTU-904 laser device, through partner manufacturers and distributors across South Korea and other international markets.

Product overview

SciGen is a biopharmaceutical company that markets and commercializes an integrated portfolio of innovative healthcare products organized across three main segments: Brand Drugs, Generics/Biosimilars, and Medical Devices. The company's product portfolio includes injectable pharmaceuticals (SciXeg® biosimilar, SciLocyte™, HERI®, Zometa®, Diphereline®, SciTropin A™, Gensulin®/SciLin™), oncology supportive care products (ISCADOR®, Zinc-S®, NeoTrace 4®), medical devices (LTU-904 laser treatment, Gensupen 2® insulin delivery device), and hormonal therapies (Lorelin). The products span therapeutic areas including endocrinology, oncology, hematology, and supportive care, with distribution across South Korea, Australia, Southeast Asia, and emerging markets worldwide.

Differentiator

Problem solved

Functional benefit

Brands

• SciXeg: Biosimilar of pegfilgrastim approved by both the FDA and EMA for oncology and hematology supportive care.
• SciTropin A
• SciLocyte

Products and services

• Lorelin Lorelin is the first GnRHa (Gonadotropin-Releasing Hormone agonist) developed in Korea with international patent approval. It is used for endocrinology, oncology, and OBGY indications, currently marketed in South Korea.
• SciXeg® (pegfilgrastim biosimilar 6mg) SciXeg is a G-CSF (granulocyte colony-stimulating factor) biosimilar of pegfilgrastim supplied as a 6mg pre-filled syringe injection, approved by both the FDA and EMA, and used for oncology and hematology supportive care. Marketed in South Korea.
• LTU-904 LTU-904 is an innovative low-level laser treatment medical device for patients suffering from Post-Mastectomy Lymphoedema. Marketed in South Korea.
• Gensupen 2® Gensupen 2 is an insulin delivery medical device used with injectable pharmaceutical products, distributed in emerging markets and used by thousands of patients worldwide.
• Zinc-S® Zinc-S is a zinc sulfate hydrate pharmaceutical product for the prevention of low zinc levels, used in oncology applications. Marketed in South Korea.
• NeoTrace 4® NeoTrace 4 is a sterile, nonpyrogenic solution of zinc, copper, manganese, and chromium used to prevent depletion of endogenous trace element stores and subsequent deficiency symptoms. Marketed in South Korea for oncology.
• ISCADOR® ISCADOR is a Swiss-made mistletoe (Viscum album) extract product addressing oncology support needs. Marketed in South Korea.
• HERI® HERI is an immune modulator containing Thymosin α1 designed to boost immune defense in immunocompromised patients. Marketed in South Korea.
• SciLocyte™ (Filgrastim in pre-filled syringe) SciLocyte is the first Filgrastim in pre-filled syringe (PFS) format, a G-CSF product for increasing Absolute Neutrophil Count (ANC) with proven efficacy and safety. Currently marketed in the Philippines.
• Zometa® (zoledronic acid) Zometa is a ready-to-use zoledronic acid formulation for bone-related conditions, marketed in Australia, Brunei, Hong Kong, Indonesia, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam.
• Diphereline® Diphereline is a prolonged-acting GnRH agonist with proven efficacy and safety data since 1986, used in endocrinology applications.
• SciTropin A™ (recombinant human growth hormone) SciTropin A is a European quality recombinant human growth hormone (rhGH) supplied in a ready-to-use format for short stature correction. Currently marketed in Australia, Philippines, South Korea, Singapore, Vietnam, Malaysia, Hong Kong, and Thailand.
• Gensulin® / SciLin™ (recombinant human insulin) Gensulin (also marketed as SciLin) is a high-quality European recombinant human insulin with 20 years of experience confirming effectiveness, safety, and stability. Available in multiple formulations including Scilin N, Scilin R, and Scilin M30, distributed in emerging markets.

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Potential Manufacturers and Distributors (unnamed)coreChannel Partner/ Reseller/ DistributorSciGen partners with manufacturers and distributors across different markets to represent their products. The partnership involves reaching out to potential partners, conducting partner due diligence, market analysis, product finalization, and agreement negotiation and finalization.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Celltrion: South Korea's leading biosimilar developer and manufacturer, with FDA/EMA approved pegfilgrastim and filgrastim biosimilars that directly compete with SciXeg and SciLocyte. Directly comparable in product category, regulatory strategy, and APAC commercial reach.
• Alvotech: Iceland-based pure-play biosimilar developer with FDA/EMA approvals across oncology and immunology, actively expanding APAC distribution partnerships. Comparable as a biosimilar-focused company pursuing multi-territory regulatory commercialization.
• Samsung Bioepis: Korean biosimilar specialist developing and commercializing multiple oncology and immunology biosimilars with FDA/EMA approvals. Directly comparable as a Korean-headquartered biosimilar player with global regulatory reach.
• Intas Pharmaceuticals: India-based specialty generics and biosimilar manufacturer with global footprint via Accurex and other channels, active in oncology and immunology biosimilars. Comparable in product mix and multi-territory partner-driven commercialization.
• Stada Arzneimittel: German specialty generics and biosimilar manufacturer with broad European specialty footprint and growing APAC presence. Comparable as a multi-territory specialty/generics player with in-licensing and partner distribution focus.
• Biocon Biologics: India-headquartered developer of biosimilars (pegfilgrastim, filgrastim, trastuzumab, etc.) with FDA/EMA approvals and emerging APAC commercialization. Direct peer via overlapping biosimilar assets and emerging-markets distribution playbook.

Broad incumbents

• Lupin Limited: India-headquartered specialty pharmaceutical company with branded specialty, biosimilars, and complex generics across global markets including APAC and emerging regions. Comparable via specialty pharma breadth and partner distribution emphasis.
• Dr. Reddy's Laboratories: India's largest specialty pharmaceutical company with proprietary products, biosimilars (including G-CSF franchise), and significant APAC and emerging-markets presence. Comparable via biosimilar G-CSF overlap and broad specialty pharma portfolio.
• Cipla: India-based global pharmaceutical company with deep presence in oncology, respiratory, and specialty segments across APAC and emerging markets, including biosimilar and branded specialty franchises. Comparable as a large incumbent with overlapping therapeutic-area breadth and emerging-markets focus.
• LG Chem Life Sciences: Korean diversified chemical and life sciences business with growing specialty pharma and biosimilar investments, including growth hormone and oncology supportive care franchises. Comparable as a Korean specialty player expanding APAC and global biosimilar franchises.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/scigenkorea

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SciGen Korea Ltd.